MMAI explained

Image Class:skin-invert-image
Width:225px
Class:Selective serotonin releasing agent
Entactogen
Atc Prefix:None
Legal Status:Uncontrolled
Cas Number:136468-19-4
Pubchem:131575
Chemspiderid:116274
Unii:JF10U4I82P
Synonyms:MMAI; MMAi; 5-Methoxy-6-methyl-2-aminoindan
Iupac Name:5-Methoxy-6-methyl-2,3-dihydro-1H-inden-2-amine
C:11
H:15
N:1
O:1
Smiles:Cc1cc2CC(N)Cc2cc1OC
Stdinchi:1S/C11H15NO/c1-7-3-8-4-10(12)5-9(8)6-11(7)13-2/h3,6,10H,4-5,12H2,1-2H3
Stdinchikey:JLESVLCTIOAHPT-UHFFFAOYSA-N

5-Methoxy-6-methyl-2-aminoindane (MMAI) is a drug of the 2-aminoindane family developed in the 1990s by a team led by David E. Nichols at Purdue University.[1] It acts as a less neurotoxic and highly selective serotonin releasing agent (SSRA) and produces entactogenic effects in humans.[1] [2] [3] [4] The drug has been sold as a designer drug and research chemical online since 2010.

Interactions

See also: MDMA/citalopram.

Pharmacology

Pharmacodynamics

The drug is one of the only known monoamine releasing agents (MRAs) with greater than 100-fold selectivity for the serotonin transporter (SERT) over the dopamine transporter (DAT).[5] Receptor interaction data for MMAI have also been reported.[6]

MMAI has been shown to relieve stress-induced depression in rats more robustly than sertraline,[7] and as a result it has been suggested that SSRAs like MMAI and 4-methylthioamphetamine (4-MTA) could be developed as novel antidepressants with a faster onset of therapeutic action and superior effectiveness to current antidepressants such as the selective serotonin reuptake inhibitors (SSRIs).[8]

MMAI alone does not appear to produce serotonergic neurotoxicity with either acute or chronic administration in animals.[9] [10] However, subsequent research found that a single high dose of MMAI could produce significant serotonergic neurotoxicity. In addition, combination of MMAI with the dopamine releasing agent dextroamphetamine has been found to produce dose-dependent serotonergic neurotoxicity in animals. Hence, MMAI is not a fully non-neurotoxic MDMA analogue.

Compound Monoamine release (nM) Ref
Dopamine
>10,000 86 439
114 117 1,334
MMAI 31 3,101 >10,000
134 861 2,646
698–1,765 6.6–7.2 5.8–24.8 [11] [12] [13] [14]
160–162 47–108 106–190
50–85 54–110 51–278 [15] [16] [17] [18] [19]
58.0 103
Notes: The smaller the value, the more strongly the compound produces the effect. The assays were done in rat brain synaptosomes and human potencies may be different. See also Monoamine releasing agent § Activity profiles for a larger table with more compounds. Refs: [20]

Chemistry

MMAI is the 2-aminoindane analogue of 3-methoxy-4-methylamphetamine (MMA).[21]

See also

External links

Notes and References

  1. Marona-Lewicka D, Nichols DE . Behavioral effects of the highly selective serotonin releasing agent 5-methoxy-6-methyl-2-aminoindan . European Journal of Pharmacology . 258 . 1–2 . 1–13 . June 1994 . 7925587 . 10.1016/0014-2999(94)90051-5 . 10.1.1.688.1895 .
  2. Li Q, Murakami I, Stall S, Levy AD, Brownfield MS, Nichols DE, Van de Kar LD . Neuroendocrine pharmacology of three serotonin releasers: 1-(1,3-benzodioxol-5-yl)-2-(methylamino)butane (MBDB), 5-methoxy-6-methyl-2-aminoindan (MMAi) and p-methylthioamphetamine (MTA) . The Journal of Pharmacology and Experimental Therapeutics . 279 . 3 . 1261–1267 . December 1996 . 10.1016/S0022-3565(25)21285-X . 8968349 .
  3. Rudnick G, Wall SC . Non-neurotoxic amphetamine derivatives release serotonin through serotonin transporters . Molecular Pharmacology . 43 . 2 . 271–276 . February 1993 . 10.1016/S0026-895X(25)13609-2 . 8429828 .
  4. Luethi D, Kolaczynska KE, Docci L, Krähenbühl S, Hoener MC, Liechti ME . Pharmacological profile of mephedrone analogs and related new psychoactive substances . Neuropharmacology . 134 . Pt A . 4–12 . May 2018 . 28755886 . 10.1016/j.neuropharm.2017.07.026 . 28786127 .
  5. Rudin D, Liechti ME, Luethi D . Molecular and clinical aspects of potential neurotoxicity induced by new psychoactive stimulants and psychedelics . Exp Neurol . 343 . 113778 . September 2021 . 34090893 . 10.1016/j.expneurol.2021.113778 . free .
  6. Luethi D, Kolaczynska KE, Docci L, Krähenbühl S, Hoener MC, Liechti ME . Pharmacological profile of mephedrone analogs and related new psychoactive substances . Neuropharmacology . 134 . Pt A . 4–12 . May 2018 . 28755886 . 10.1016/j.neuropharm.2017.07.026 .
  7. Marona-Lewicka D, Nichols DE . The Effect of Selective Serotonin Releasing Agents in the Chronic Mild Stress Model of Depression in Rats . Stress . 2 . 2 . 91–100 . December 1997 . 9787258 . 10.3109/10253899709014740 .
  8. Scorza C, Silveira R, Nichols DE, Reyes-Parada M . Effects of 5-HT-releasing agents on the extracellullar hippocampal 5-HT of rats. Implications for the development of novel antidepressants with a short onset of action . Neuropharmacology . 38 . 7 . 1055–1061 . July 1999 . 10428424 . 10.1016/S0028-3908(99)00023-4 . 13714807 .
  9. Johnson MP, Nichols DE . Combined administration of a non-neurotoxic 3,4-methylenedioxymethamphetamine analogue with amphetamine produces serotonin neurotoxicity in rats . Neuropharmacology . 30 . 7 . 819–822 . July 1991 . 1717873 . 10.1016/0028-3908(91)90192-e .
  10. Johnson MP, Conarty PF, Nichols DE . [3H]monoamine releasing and uptake inhibition properties of 3,4-methylenedioxymethamphetamine and p-chloroamphetamine analogues . Eur J Pharmacol . 200 . 1 . 9–16 . July 1991 . 1685125 . 10.1016/0014-2999(91)90659-e .
  11. Baumann MH, Partilla JS, Lehner KR, Thorndike EB, Hoffman AF, Holy M, Rothman RB, Goldberg SR, Lupica CR, Sitte HH, Brandt SD, Tella SR, Cozzi NV, Schindler CW . Powerful cocaine-like actions of 3,4-methylenedioxypyrovalerone (MDPV), a principal constituent of psychoactive 'bath salts' products . Neuropsychopharmacology . 38 . 4 . 552–562 . March 2013 . 23072836 . 3572453 . 10.1038/npp.2012.204 .
  12. Book: Blough B . Dopamine-releasing agents . Trudell ML, Izenwasser S . Dopamine Transporters: Chemistry, Biology and Pharmacology . 305–320 . July 2008 . 978-0-470-11790-3 . 181862653 . OL18589888W . Wiley . Hoboken [NJ] . https://bitnest.netfirms.com/external/Books/Dopamine-releasing-agents_c11.pdf .
  13. Book: Glennon RA, Dukat M . Neuropharmacology of New Psychoactive Substances (NPS) . Structure-Activity Relationships of Synthetic Cathinones . Current Topics in Behavioral Neurosciences . 32 . 19–47 . 2017 . 27830576 . 5818155 . 10.1007/7854_2016_41 . 978-3-319-52442-9 .
  14. Book: Partilla JS, Dersch CM, Baumann MH, Carroll FI, Rothman RB . Profiling CNS Stimulants with a High-Throughput Assay for Biogenic Amine Transporter Substrates . Problems of Drug Dependence 1999: Proceedings of the 61st Annual Scientific Meeting, The College on Problems of Drug Dependence, Inc . NIDA Res Monogr . 180 . 1–476 (252) . 1999 . 11680410 . https://web.archive.org/web/20230805004105/https://archives.nida.nih.gov/sites/default/files/180.pdf#page=261 . dead . August 5, 2023 . RESULTS. Methamphetamine and amphetamine potently released NE (IC50s = 14.3 and 7.0 nM) and DA (IC50s = 40.4 nM and 24.8 nM), and were much less potent releasers of 5-HT (IC50s = 740 nM and 1765 nM). [...] .
  15. Rothman RB, Baumann MH, Dersch CM, Romero DV, Rice KC, Carroll FI, Partilla JS . Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin . Synapse . 39 . 1 . 32–41 . January 2001 . 11071707 . 10.1002/1098-2396(20010101)39:1<32::AID-SYN5>3.0.CO;2-3 . 15573624 .
  16. Baumann MH, Ayestas MA, Partilla JS, Sink JR, Shulgin AT, Daley PF, Brandt SD, Rothman RB, Ruoho AE, Cozzi NV . The designer methcathinone analogs, mephedrone and methylone, are substrates for monoamine transporters in brain tissue . Neuropsychopharmacology . 37 . 5 . 1192–1203 . April 2012 . 22169943 . 3306880 . 10.1038/npp.2011.304 .
  17. Marusich JA, Antonazzo KR, Blough BE, Brandt SD, Kavanagh PV, Partilla JS, Baumann MH . The new psychoactive substances 5-(2-aminopropyl)indole (5-IT) and 6-(2-aminopropyl)indole (6-IT) interact with monoamine transporters in brain tissue . Neuropharmacology . 101 . 68–75 . February 2016 . 26362361 . 4681602 . 10.1016/j.neuropharm.2015.09.004 .
  18. Setola V, Hufeisen SJ, Grande-Allen KJ, Vesely I, Glennon RA, Blough B, Rothman RB, Roth BL . 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro . Molecular Pharmacology . 63 . 6 . 1223–1229 . June 2003 . 12761331 . 10.1124/mol.63.6.1223 . 839426 .
  19. Brandt SD, Walters HM, Partilla JS, Blough BE, Kavanagh PV, Baumann MH . The psychoactive aminoalkylbenzofuran derivatives, 5-APB and 6-APB, mimic the effects of 3,4-methylenedioxyamphetamine (MDA) on monoamine transmission in male rats . Psychopharmacology (Berl) . 237 . 12 . 3703–3714 . December 2020 . 32875347 . 10.1007/s00213-020-05648-z . 7686291 .
  20. Halberstadt AL, Brandt SD, Walther D, Baumann MH . 2-Aminoindan and its ring-substituted derivatives interact with plasma membrane monoamine transporters and α2-adrenergic receptors . Psychopharmacology (Berl) . 236 . 3 . 989–999 . March 2019 . 30904940 . 6848746 . 10.1007/s00213-019-05207-1 .
  21. Nichols DE, Marona-Lewicka D, Huang X, Johnson MP . Novel serotonergic agents . Drug des Discov . 9 . 3–4 . 299–312 . 1993 . 8400010 .